Ozempic and weight loss: side effect or intended outcome?

What did @docteurleyla actually say?

Honestly, this is a difficult video to fact-check because the transcript is largely incoherent. The auto-generated captions appear to have failed badly, likely because the creator was speaking French. What we can piece together from the caption and hashtags is that @docteurleyla, who identifies as a pharmacist, set out to explain Ozempic's weight loss effects as a "side effect" of a diabetes drug. That framing, calling weight loss an "effet indésirable" (adverse effect or side effect), is actually a historically accurate and underappreciated point. Ozempic (semaglutide) was approved for type 2 diabetes management before its weight loss properties were fully recognized and separately licensed.

The creator's core premise appears to be explaining the mechanism behind why a diabetes drug causes weight loss. That is a legitimate educational topic. Without a clean transcript, however, we cannot verify every specific claim made.

Does the science back up the core premise?

Yes, and the mechanism is well-documented. Semaglutide is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1, a hormone your gut naturally releases after eating. It works through several overlapping pathways, not a single magic switch. The weight loss is real, substantial, and now FDA-recognized under the Wegovy brand name for chronic weight management.

The key mechanisms include slowing gastric emptying (food leaves your stomach more slowly, so you feel full longer), reducing appetite signals in the hypothalamus, and lowering post-meal blood glucose spikes by stimulating insulin release only when glucose is present. Wilding et al. (2021, NEJM) showed that weekly semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults without diabetes, which was a significant finding that shifted how clinicians think about obesity treatment. The weight loss is not purely a side effect in the traditional sense. It is a direct pharmacological action.

What did they get right or wrong?

The framing of weight loss as an "effet indésirable" deserves some scrutiny. In strict regulatory language, when Ozempic was first approved for diabetes, weight loss was listed as a secondary effect rather than the primary indication. That is technically accurate. But calling it an adverse effect in a consumer-facing video risks confusion. Adverse effects usually imply harm. Weight loss in this context is generally an intended and beneficial secondary outcome for many patients with type 2 diabetes who also carry excess weight.

If the creator correctly explained the GLP-1 mechanism, including appetite suppression and gastric emptying, that would align with consensus science. What creators in this space frequently get wrong is overstating durability. Weight returns in most patients after stopping semaglutide, as shown by Wilding et al. (2022, Diabetes, Obesity and Metabolism), where patients regained approximately two-thirds of lost weight within a year of discontinuation. If the video did not address this, that is a meaningful omission.

What should you actually know?

Semaglutide works. The clinical evidence is unusually strong for a weight management drug, and the SELECT trial (Lincoff et al., 2023, NEJM) added cardiovascular outcome data showing a 20% reduction in major adverse cardiovascular events in people with obesity and established cardiovascular disease. That is not nothing.

But context matters. Ozempic is specifically approved for type 2 diabetes management. Wegovy contains the same active ingredient at a higher approved dose for weight management. These are not interchangeable prescriptions, and the compounded versions circulating on the market are not equivalent to either brand-name product. Common side effects are real and frequently underplayed in social media content: nausea, vomiting, gastroparesis risk with long-term use, and rare but serious pancreatitis concerns. Anyone considering semaglutide for weight management should have that conversation with a licensed clinician, not base their decision on a TikTok explainer, however well-intentioned.